Literature DB >> 24986534

Bugs or drugs: are probiotics safe for use in the critically ill?

Lindsay M Urben1, Jennifer Wiedmar, Erica Boettcher, Rodrigo Cavallazzi, Robert G Martindale, Stephen A McClave.   

Abstract

Probiotics are living microorganisms which have demonstrated many benefits in prevention, mitigation, and treatment of various disease states in critically ill populations. These diseases include antibiotic-associated diarrhea, Clostridium difficile diarrhea, ventilator-associated pneumonia, clearance of vancomycin-resistant enterococci from the GI tract, pancreatitis, liver transplant, major abdominal surgery, and trauma. However, their use has been severely limited due to a variety of factors including a general naïveté within the physician community, lack of regulation, and safety concerns. This article focuses on uses for probiotics in prevention and treatment, addresses current concerns regarding their use as well as proposing a protocol for safe use of probiotics in the critically ill patient.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24986534     DOI: 10.1007/s11894-014-0388-y

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  75 in total

Review 1.  Ventilator associated pneumonia: perspectives on the burden of illness.

Authors:  D Cook
Journal:  Intensive Care Med       Date:  2000       Impact factor: 17.440

Review 2.  Probiotics in the intensive care unit.

Authors:  Lee E Morrow; Vijaya Gogineni; Mark A Malesker
Journal:  Nutr Clin Pract       Date:  2012-04       Impact factor: 3.080

Review 3.  Antibiotic resistance: the pros and cons of probiotics.

Authors:  Patrice Courvalin
Journal:  Dig Liver Dis       Date:  2006-12       Impact factor: 4.088

4.  Effects of probiotics on the severity of experimental acute pancreatitis.

Authors:  M A T Muftuoglu; S Isikgor; S Tosun; A Saglam
Journal:  Eur J Clin Nutr       Date:  2006-04       Impact factor: 4.016

5.  Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial.

Authors:  Nada Rayes; Daniel Seehofer; Tom Theruvath; Reinhold A Schiller; Jan M Langrehr; Sven Jonas; Stig Bengmark; Peter Neuhaus
Journal:  Am J Transplant       Date:  2005-01       Impact factor: 8.086

6.  Synbiotics, prebiotics, glutamine, or peptide in early enteral nutrition: a randomized study in trauma patients.

Authors:  Alenka Spindler-Vesel; Stig Bengmark; Irena Vovk; Ognjen Cerovic; Lidija Kompan
Journal:  JPEN J Parenter Enteral Nutr       Date:  2007 Mar-Apr       Impact factor: 4.016

7.  Recommendations for probiotic use-2011 update.

Authors:  Martin H Floch; W Allan Walker; Karen Madsen; Mary Ellen Sanders; George T Macfarlane; Harry J Flint; Levinus A Dieleman; Yehuda Ringel; Stefano Guandalini; Ciaran P Kelly; Lawrence J Brandt
Journal:  J Clin Gastroenterol       Date:  2011-11       Impact factor: 3.062

8.  Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.

Authors:  Marc Gh Besselink; Hjalmar C van Santvoort; Erik Buskens; Marja A Boermeester; Harry van Goor; Harro M Timmerman; Vincent B Nieuwenhuijs; Thomas L Bollen; Bert van Ramshorst; Ben Jm Witteman; Camiel Rosman; Rutger J Ploeg; Menno A Brink; Alexander Fm Schaapherder; Cornelis Hc Dejong; Peter J Wahab; Cees Jhm van Laarhoven; Erwin van der Harst; Casper Hj van Eijck; Miguel A Cuesta; Louis Ma Akkermans; Hein G Gooszen
Journal:  Lancet       Date:  2008-02-14       Impact factor: 79.321

Review 9.  Probiotics for preventing and treating nosocomial infections: review of current evidence and recommendations.

Authors:  Warren Isakow; Lee E Morrow; Marin H Kollef
Journal:  Chest       Date:  2007-07       Impact factor: 9.410

10.  Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study.

Authors:  Bengt Klarin; Göran Molin; Bengt Jeppsson; Anders Larsson
Journal:  Crit Care       Date:  2008-11-06       Impact factor: 9.097

View more
  4 in total

1.  Evidence in the eye of the beholder: about probiotics and VAP prevention.

Authors:  Stijn Blot; Antonio Torres; Bruno Francois
Journal:  Intensive Care Med       Date:  2016-04-13       Impact factor: 17.440

Review 2.  Probiotics for the prevention of Hirschsprung-associated enterocolitis.

Authors:  Fan Mei; Mei Wu; Li Zhao; Kaiyan Hu; Qianqian Gao; Fei Chen; Joey Sw Kwong; Yanan Wang; Xi Ping Shen; Bin Ma
Journal:  Cochrane Database Syst Rev       Date:  2022-04-26

Review 3.  The Intestinal Microbiome in Infectious Diseases: The Clinical Relevance of a Rapidly Emerging Field.

Authors:  Vanessa C Harris; Bastiaan W Haak; Michaël Boele van Hensbroek; Willem J Wiersinga
Journal:  Open Forum Infect Dis       Date:  2017-07-08       Impact factor: 3.835

4.  Response to "Reassessing the death risk related to probiotics in critically ill patients".

Authors:  William Manzanares; Paul E Wischmeyer
Journal:  Crit Care       Date:  2017-02-27       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.